

SEP. 29. 2008 1:30PM

J & J WH6114

NO. 1930 P. 1/2

JOHNSON & JOHNSON  
CORPORATE HEADQUARTERS  
PATENT LAW DEPARTMENT  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NEW JERSEY 08933-7003

RECEIVED  
CENTRAL FAX CENTER

SEP 29 2008

F A C S I M I L E T R A N S M I S S I O N S C O V E R S H E E T

DATE: September 29, 2008

TO: USPTO  
Attn: Caroline Johnson

FACSIMILE NO.: 571-273-8300

FROM: Paul A. Coletti

TELEPHONE NO.: (732) 524-2815 FACSIMILE NO.: (732) 524-2134

NUMBER OF PAGES INCLUDING THIS COVER SHEET: 2

COMMENTS: Documents Transmitted: Abstract

Applicant :	Gregory Kopia	Confirmation No. 1106
Serial No.:	09/575,480	Art Unit: 3743
Filed :	May 16, 2000	
For :	Drug Combinations Useful for Prevention of Restenosis	
Docket :	CRD-850USNP	

Attached herewith is the abstract for the above-captioned application.

**RECEIVED  
CENTRAL FAX CENTER****SEP 29 2008**

- 22 -

5

**ABSTRACT**

The current invention comprises an approach to solving the clinical problem of restenosis, which involves the administration of combinations of drugs to patients undergoing PTCA or stent implantation. In one embodiment of the invention, an antiproliferative agent such as rapamycin, vincristine or taxol is administered in combination with the antiinflammatory agent, dexamethasone, to patients systemically, either subcutaneously or intravenously. In another embodiment of the invention, the antiproliferative and antiinflammatory agents are bound in a single formulation to the surface of a stent by means of incorporation within either a biodegradable or biostable polymeric coating. Alternatively, such drug combinations could be incorporated into a stent constructed with a grooved reservoir.

CRD-850